Arax Advisory Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.79M | Buy |
53,764
+45,265
| +533% | +$5.96M | 0.05% | 399 |
|
|
2026
Q1 | $1.18M | Sell |
8,499
-20,855
| -71% | -$2.92M | 0.03% | 388 |
|
|
2025
Q4 | $3.6M | Sell |
29,354
-34,307
| -54% | -$4.17M | 0.1% | 159 |
|
|
2025
Q3 | $7.07M | Buy |
63,661
+58,541
| +1,143% | +$6.65M | 0.1% | 163 |
|
|
2025
Q2 | $623K | Buy |
5,120
+2,515
| +97% | +$268K | 0.03% | 338 |
|
|
2025
Q1 | $292K | Buy |
2,605
+668
| +34% | +$68.9K | 0.02% | 436 |
|
|
2024
Q4 | $179K | Buy |
1,937
+1,668
| +620% | +$150K | 0.01% | 516 |
|
|
2024
Q3 | $22.6K | Buy |
269
+60
| +29% | +$4.58K | ﹤0.01% | 1038 |
|
|
2024
Q2 | $14.3K | Buy |
209
+93
| +80% | +$6.21K | ﹤0.01% | 1100 |
|
|
2024
Q1 | $8.53K | Sell |
116
-48
| -29% | -$3.69K | ﹤0.01% | 801 |
|
|
2023
Q4 | $13.3K | Buy |
164
+60
| +58% | +$4.67K | ﹤0.01% | 716 |
|
|
2023
Q3 | $7.8K | Sell |
104
-13
| -11% | -$1K | ﹤0.01% | 778 |
|
|
2023
Q2 | $9.01K | Sell |
117
-41
| -26% | -$3.27K | ﹤0.01% | 729 |
|
|
2023
Q1 | $13.1K | Buy |
158
+42
| +36% | +$3.48K | ﹤0.01% | 646 |
|
|
2022
Q4 | $9.98K | Buy |
116
+15
| +15% | +$1.19K | ﹤0.01% | 651 |
|
|
2022
Q3 | $6K | Sell |
101
-145
| -59% | -$9.14K | ﹤0.01% | 747 |
|
|
2022
Q2 | $15K | Buy |
246
+181
| +278% | +$11.2K | ﹤0.01% | 593 |
|
|
2022
Q1 | $4K | Buy |
65
+36
| +124% | +$2.3K | ﹤0.01% | 822 |
|
|
2021
Q4 | $2K | Sell |
29
-152
| -84% | -$10.5K | ﹤0.01% | 881 |
|
|
2021
Q3 | $13K | Buy |
+181
| New | +$12.7K | ﹤0.01% | 606 |
|
|
2020
Q4 | – | Sell |
-380
| Closed | -$24K | – | 742 |
|
|
2020
Q3 | $24K | Buy |
+380
| New | +$26.4K | ﹤0.01% | 460 |
|
|
2018
Q4 | $7K | Sell |
106
-349
| -77% | -$24.4K | ﹤0.01% | 463 |
|
|
2018
Q3 | $35K | Sell |
455
-1,158
| -72% | -$87.5K | 0.01% | 328 |
|
|
2018
Q2 | $114K | Sell |
1,613
-121
| -7% | -$8.54K | 0.05% | 142 |
|
|
2018
Q1 | $130K | Buy |
1,734
+8
| +0.5% | +$636 | 0.07% | 115 |
|
|
2017
Q4 | $123K | Sell |
1,726
-11
| -0.6% | -$835 | 0.05% | 132 |
|
|
2017
Q3 | $140K | Sell |
1,737
-95
| -5% | -$7.26K | 0.07% | 118 |
|
|
2017
Q2 | $129K | Buy |
1,832
+798
| +77% | +$53.1K | 0.06% | 133 |
|
|
2017
Q1 | $70K | Buy |
1,034
+323
| +45% | +$22.7K | 0.03% | 161 |
|
|
2016
Q4 | $51K | Buy |
+711
| New | +$52.8K | 0.03% | 165 |
|
Other funds holding GILD
Arax Advisory Partners's GILD Position: Q2 2026 in Review
Arax Advisory Partners increased its Gilead Sciences (GILD) stake by 533% in Q2 2026, buying an estimated $5.96M and bringing the position to 53,764 shares worth $6.79M. The position accounts for 0.05% of the portfolio, ranked #399.
Arax Advisory Partners first reported a position in GILD in Q4 2016 and has held it in 30 quarters since. The position peaked at $7.07M in Q3 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Arax Advisory Partners held 53,764 shares of Gilead Sciences worth $6.79M as of Q2 2026.
- Arax Advisory Partners bought 45,265 Gilead Sciences shares in Q2 2026, an estimated $5.96M.
- Gilead Sciences made up 0.05% of Arax Advisory Partners's portfolio in Q2 2026, its #399 holding.
- Arax Advisory Partners first reported a position in Gilead Sciences in Q4 2016 and has held it in 30 quarters since.
- Arax Advisory Partners's Gilead Sciences position peaked at $7.07M in Q3 2025.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.